ProShares Trust - ProShares UltraShort S&P500 -2x Shares
SDS
Market Cap$31.04M
Close$
$-6.98
142.1% downside
Current Fair Value
142.1% downsideOvervalued by 142.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $31.04 Million |
|---|---|
| Enterprise Value | $35.19 Million |
| Dividend Yield | $1.44177 (7.17961939840393%) |
| Earnings per Share | $0 |
| Beta | -1.96 |
| Outstanding Shares | 1,893,127 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.36 |
|---|---|
| PEG | -13.04 |
| Price to Sales | 1.84 |
| Price to Book Ratio | 1.27 |
| Enterprise Value to Revenue | 1.95 |
| Enterprise Value to EBIT | -3.97 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.43 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...